The Data
/
Stocks
/ BIO
Equity · Healthcare
BIO
NYSE
Bio-Rad Laboratories, Inc.
$378
−0.79% vs prior close
Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 28, 2026
1D
1M
3M
1Y
5Y
All
Price · Chart
Our own end-of-day closes
62 sessions
The line runs $297 on 1 July through $378 on 28 September, on a scale from $250 to $400. Days the market did not trade hold the previous close, flat.
Interactive BIO price chart by TradingView (requires JavaScript).
The chart above plots the price of BIO over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 62 sessions over that window: $297 on 1 July 2026 through $378 on 28 September 2026.
Market cap
$10.2B
52-week range
$242 – $390.31
Avg volume
19.1K
Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 28, 2026
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. is a multinational company that develops, manufactures, and markets instruments, systems, reagents, and consumables for the life science and clinical diagnostics markets. The company operates in two segments: Life Science, which provides products for research and biopharmaceutical laboratories, and Clinical Diagnostics, which offers diagnostic test systems and related products for clinical laboratories. Its customers include universities, research organizations, government agencies, pharmaceutical and biotechnology companies, food producers, hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.
Company
Founded
1952
Employees
8,300
Headquarters
Hercules
Exchange
NYSE
Sector
Healthcare
Class
Equity
Filings 4 sets
BIO reported financials
SEC EDGAR XBRL
BIO reported revenue of $2.6B for the fiscal year ended 31 Dec 2025. Net income over the same period was $759.9M.
Figure
Reported
Period
Revenue
$2.6B
31 Dec 2025
fiscal year
Net income
$759.9M
31 Dec 2025
fiscal year
Diluted EPS
$27.85
31 Dec 2025
fiscal year
Total assets
$10.3B
30 Jun 2026
at period end
Total equity
$7.2B
30 Jun 2026
at period end
Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
BIO earnings
SEC EDGAR
Date
Period
EPS
Revenue
30 Jun 2026
Q2 2026
$13.85
$651M
31 Mar 2026
Q1 2026
$-19.55
$592M
31 Dec 2025
FY 2025
$27.85
$2.58B
30 Sep 2025
Q3 2025
$-12.70
$653M
30 Jun 2025
Q2 2025
$11.67
$652M
31 Mar 2025
Q1 2025
$2.29
$585M
31 Dec 2024
FY 2025
$-25.57
$2.57B
30 Sep 2024
Q3 2024
$23.34
$650M
Next report no date announced in SEC filings yet
Reported figures & scheduled dates · SEC EDGAR filings
10 of the 45 institutional funds we track reported a BIO position for the quarter ended 30 Jun 2026 — a combined $155.7M; the latest of those filings landed 02 Sep 2026.
Source: SEC EDGAR 13F filings
BIO fails-to-deliver
SEC CNS data
On 25 Aug 2026, 17,170 shares of BIO failed to deliver (about $6.6M).
Settlement date
Shares failed
Notional
% of shares out
25 Aug 2026
17,170
$6.6M
0.064%
18 Aug 2026
13,658
$4.9M
0.051%
Source: SEC fails-to-deliver (CNS) data